The high expression of CD47 on RBCs means that RBCs bind to CD47 antibodies preferentially,353 but it is still possible to develop antibodies with antitumor activity and without hematological toxicity since the molecular conformation of CD47 on tumor cells is distinct from that of CD47 on RBCs.354–356 TJC4 was designed with the above concept and is in a phase II clinical trial currently.357. Here, CD47 is linked to neoplasm.